CANCER PUBLICATIONS

  1. Navalkele Pournima, Jones SM, Jones JK, Salazar JD, Toy PC, Iyer RV, Herrington B. Osteosarcoma tumor thrombus: a case report with review of the literature. Texas Heart Institute Journal 2013;40(1):75-78
  2. de Torres JP, Casanova C, Marin JM, Zagaceta J, Alcaide AB, Seijo LM, Campo A, Carrizo S, Montes U, Cordoba-Lanus E, Baz-Davila R, Aguirre-Jaime A, Celli BR and Zulueta JJ. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study. Respiratory Medicine 2013;107:702-7.
  3. de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, Baz-Davilla R, Zulueta JJ, Aguirre-Jamie A, Saetta M, Cosio MG and Celli BR. Lung cancer in patients with COPD: Incidence and predicting factors. American Journal of Respiratory and Critical Care Medicine 2011;184:913-9.
  4. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S and Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 2011;117(4):662-76.
  5. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintas-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S and Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 2011;117(2):327-35.
  6. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW and Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Journal of Clinical Investigation 2011;121(1):396-409.
  7. Cortes J, Quintas-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S and Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 2011;117(3):572-80.
  8. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J and Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011;117(1):110-5.
  9. Dubovsky JA, Wang D, Powers JJ, Smith M, Wright K, Sotomayor EM and Pinilla-Ibarz JA. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leukemia Research 2011;35(3):394-404.
  10. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE and Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117(9):1800-11.
  11. Jabbour E, Cortes J and Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 2011;117(5):897-906.
  12. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Kantarjian H, Champlin R and De Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011;117(13):3641-7.
  13. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB and Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 2011;117(6):1822-7.
  14. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ and Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2011;117(6):1236-44.
  15. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W and Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 2011;117(3):920-7.
  16. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M and Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Supportive Care in Cancer 2011;19(1):19-26.
  17. Padron E, Hazlehurst L and Pinilla-Ibarz J. Molecular pathogenesis of BCR-ABL in chronic myeloid leukemia. In: Mufti G and Saba H. Advances in Malignant Hematology. Blackwell Publishing Limited; 2
  18. Pinilla-Ibarz J, Michael Mauro M and Cortes J. Imatinib intolerance in chronic myeloid leukemia: definitions and clinical implications. Cancer 2011;117(4):668-97.
  19. Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA and Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leukemia Research 2011;35(3):301-4.
  20. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G and Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011;117(5):982-91.
  21. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H and Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 2011;117(10):2145-55.
  22. Agrawal M, Garg RJ, Kantarjian H and Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep 2010;12(5):302-13.
  23. Agrawal M, Garg RJ, Cortes J and Quintas-Cardama A. Tyrosine kinase inhibitors: the first decade. Current Hematology and Malignancy Reports 2010;(2):70-80.
  24. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R and Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood 2010;116(23):5074-5.
  25. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE and Hosing C._ Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy_. Leukemia and Lymphoma 2010;51(8):1478-84.
  26. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortes JE and Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. [Clinical Lymphoma, Myeloma & Leukemia][1] 2010;10(3):205-10.
  27. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ and Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 2010;24(3):666-8.
  28. Carter BZ, Mak DH, Cortes J and Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Seminars in Hematology 2010;47(4):362-70.
  29. Cortes J. Towards a cure for chronic myeloid leukemia: are we there yet? Seminars in Hematology 2010;47(4):299-301.
  30. Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, Hamerschlak N, Pagnano K, Pasquini R and Meillon L. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer 2010;116(21):4991-5000.
  31. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J and Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. Journal of Clinical Oncology 2010; 28(3):392-7.
  32. Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A and Seiter K. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Journal of Clinical Oncology 2010;28(27):4207-13.
  33. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H and Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010;116(9):2174-9.
  34. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE and Ravandi F. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer 2010;116(2):369-6.
  35. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M and Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Journal of Clinical Oncology 2010;28(16):2755-60.
  36. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA and Perrotti D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010;140(5):652-5.
  37. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dunzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J and Kantarjian HM. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010;24(7):1299-1301.
  38. Jabbour E, Kantarjian H and Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how and which one? Seminars in Hematology 2010;47(4):344-53.
  39. Jabbour E, Cortes J and Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evidence 2010;4:207-13.
  40. Jabbour E, Fullmer A, Cortes JE and Kantarjian H. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clinical Lymphoma, Myeloma & Leukemia 2010;10:S6-S13.
  41. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP and Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116(16):3830-4.
  42. Jabbour E, Thomas D, Cortes J, Kantarjian HM and O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 2010;116(10):2290-300.
  43. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H and Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood 2010;115(26):5428-9.
  44. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM and Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biology of Blood and Marrow Transplantation 2009;16(4):543-7.
  45. Kantarjian HM, Cortes J, La Rosee P and Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 2010;116(6):1419-30.
  46. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J and Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. Journal of Clinical Oncology 2010;28(2):285-91.
  47. Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S and Ottmann O. Phase I study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer 2010;116(11):2665-72.
  48. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M and Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116(22);4422-9.
  49. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D and Baccarani M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine 2010;362(24):2260-70.
  50. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J and O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leukemia and Lymphoma 2010;51(3):475-80.
  51. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J and O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116(24):5568-74.
  52. Kim HK, Zhang Y, Gwak YS, Abdi S. Pheny N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy induced neuropathic pain in rats. Anesthesiology 2010;112(1):432-9.
  53. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W and Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 2010;116(17):4063-8.
  54. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss MA, Jurcic JG, Frattini MG and Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T Cell responses in patients with complete remission from Acute Myeloid Leukemia (AML). Blood 2010 Jul 15;116(2):171-9.
  55. Parikh SA, Kantarjian HM, Richie MA, Cortes JE and Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leukemia and Lymphoma 2010;51(2):269-74.
  56. Pinilla-Ibarz J and McQuary A. Chronic Lymphocytic Leukemia: putting new treatment options into perspective. Cancer Control 2010;17(2 suppl):4-15.
  57. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R and Cortes JE._ Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion_. Cancer 2010;116(2):377-86.
  58. Quintas-Cardama A, Kantarjian H and Cortes JE. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia 2010;10:S14-S19.
  59. Quintas-Cardama A, Kantarjian H and Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Seminars in Hematology 2010;47(4):371-380.
  60. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M and Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology 2010;28(11):1856-1862.
  61. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S and Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 2010;116(26):5818-5823.
  62. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J and Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leukemia Research 2010;34(6):752-756.
  63. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J and Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116(12):2070-2077.
  64. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S and Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer 2010;116(22):5272-5278.
  65. Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C and Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010;116(16):3852-3861.
  66. Saglio G, Kantarjian H, Holyoake T, Ranganathan A and Cortes JE. Proceedings of the third global workshop on chronic myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia 2010;10(6):443-451.
  67. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H and Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. Cancer 2010;116(10):2366-2371.
  68. Santos FP, Kantarjian H, Cortes J and Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Current Opinion in Investigational Drugs 2010;11(12):1450-1465.
  69. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J and Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. British Journal of Haematology 2010;150(3):303-312.
  70. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R and Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. Journal of Cellular and Molecular Medicine 2010:14(6B):1777-1792.
  71. Swords R, Alvarado Y, Cortes J and Giles FJ. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Current Hematology and Malignancy Reports 2007;2(2):83-88.
  72. Szabo SM, Levy AR, Davis C, Holyoake TL and Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value in Health 2010;13(1):103-111.
  73. Thomas DA, O'Brien S, Cortes J and Kantarjian H. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Current Hematology and Malignancy Reports 2007;2(3):183-189.
  74. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J and Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology 2010;28(24):3880-3889.
  75. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J and Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone regimen. Cancer 2010;116(19):4580-4589.
  76. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB and Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 2010;116(13):3152-3159.
  77. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM and De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 2010;116(15):3631-3637.
  78. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J and Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leukemia and Lymphoma 2010;51(5):778-
  79. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G and Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116(11):2673-2681.
  80. Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R and Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Science 2010;101(9):2005-2010.
  81. Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF and Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemiamild anemia. Journal of Clinincal Oncology 2011;29(15):e434-e436.
  82. Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J and Stone RM. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. Journal of Clinical Oncology 2009;27(21):3472-3479.
  83. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J and Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009;115(16):3709-3718.
  84. Ault P, Cortes J, Lynn A, Keating M and Verstovsek S. Pregnancy in a patient with hypereosinophilic syndrome. Leukemia Research 2009;33(1):186-7.
  85. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J and Hehlmann R. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology 2009;27(35):6041-6051.
  86. Bello C and Pinilla-Ibarz J. Biologic therapies for AML/MDS. In: Grewal IS, ed. Emerging Protein Biotherapeutics. CRC Press; 2
  87. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S and Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 2009;115(14):3217-21.
  88. Cataldo VD, Cortes J and Quintas-Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Review of Anticancer Therapy 2009;9(7):875-884.
  89. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortes JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B and Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clinical Lymphoma and Myeloma 2009;9 Suppl 3:S261-S265.
  90. Cheson BD, Cortes JE and Jagannath S. Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia. Clinical Lymphoma and Myeloma 2009;9(4):266.
  91. Cole S, Kantarjian H, Ault P and Cortes JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clinical Lymphoma and Myeloma 2009;9(4):324-7.
  92. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC and Sandler RS. Selenium, folate and colon cancer. Nutrition and Cancer 2009;61(2):165-78.
  93. Cortes JE. Chronic myeloid leukemia: where do we go now? Clinical Lymphoma and Myeloma 2009;9(Suppl 4):S374-5.
  94. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP and Hughes TP. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology 2009; 28(3):424-30.
  95. Cortes J and De Keersmaecker K. T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1. Leukemia and Lymphoma 2009;50(3):321-2.
  96. Cortes JE, Egorin MJ, Guilhot F, Molimard M and Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009;23(9):1537-1544.
  97. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J and Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology 2009;28(3):398-404.
  98. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M and Radich J. High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses. Journal of Clinical Oncology 2009;27(28):4754-9.
  99. Cortes JE, Kantarjian H and Wierda W. Chronic Myeloid Leukemia. In: Conn's Current Therapy. Pennsylvania: W. B. Saunders Company; 2009: 456-463.
  100. Dubovsky JA, McNeal D, Powers JJ, Sotomayor E and Pinilla-Ibarz J. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clinical Cancer Research 2009;15(10):3406-15.
  101. Fava C and Cortes J. Optimizing first-line therapy for patients with chronic myeloid leukemia. Seminars in Hematology 2009;46(2 Suppl 3):S5-10.
  102. Fava C, Cortes JE, Kantarjian H and Jabbour E. Standard management of patients with chronic myeloid leukemia. Clinical Lymphoma and Myeloma 2009;9(Suppl 4):S382-90.
  103. Fava C, Kantarjian H, Cortes J and Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Design, Development and Therapy 2009;2:233-3.
  104. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J and Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009;113(21):5058-63.
  105. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H and Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 2009;23(7):1297-1302.
  106. Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z and Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114(20):4361-8.
  107. Hazlehurst LA, Bewry NN, Nair RR and Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 2009;16(2):100.
  108. Jabbour E, Cortes JE and Kantarjian H. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clinical Lymphoma and Myeloma 2009;9(Suppl 3):S272-S279.
  109. Jabbour E, Cortes J and Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncology 2009;4(1):3-10.
  110. Jabbour E, Hochhaus A, Cortes J, La Rosee P and Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2009;24(1):6-12.
  111. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG and Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114(10):2037-43.
  112. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA and Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 Trial. Cancer 2009;115(17):3924-34.
  113. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, Dipersio J, Muller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C and Tallman MS. Phase III study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113(25):6322-9.
  114. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J and Druker BJ. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115(3):551-60.
  115. Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J and Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115(18):4136-47.
  116. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E and Cortes J. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. Journal of Clinical Oncology 2009;27(22):3659-63.
  117. Khoury HJ, Guilhot F, Hughes TP, Kim DW and Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009;115(7):1381-94.
  118. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F and Albitar M. Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome. Clinical Cancer Research 2009;15(11):3820-6.
  119. Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J and Albitar M. BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors. Acta Haematol 2009;121(1):27-31.
  120. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M and Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Molecular Cancer Therapeutics 2009;8(9):2509-16.
  121. Mustjoki S, Ekblom M, Almqvist A, Arstila P, Dybedal I, Ebeling F, Gedde-Dahl T, Hjorth-Hansen H, Hoglund M, Koivunen E, Koskenvesa P, Kovanen P, Laine J, Laurinolli T, Liesveld J, Lundan T, Paquette R, Pinilla-Ibarz J, Rauhala A, Sha N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L and Porkka K. Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. Leukemia 2009;23(8):1398-405.
  122. Nussenzveig RH, Cortes J, Sever M, Quintas-Cardama A, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H and Verstovsek S. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. International Journal of Hematology 2009;90(1):58-63.
  123. O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M and Wetzler M; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network 2009;7(9):984-1023.
  124. Pinilla-Ibarz J. A new era in the treatment of Chronic Myeloid Leukemia. Cancer Control 2009;16(2).
  125. Pinilla-Ibarz J, Bijal Sha B and Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control 2009;16(2):141.
  126. Pinilla-Ibarz J and Quintas-Cardama A. New agents in the treatment of chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network 2009;7(9):1028-37.
  127. Quintas-Cardama A and Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Current Oncology Reports 2009;11(5):337-45.
  128. Quintas-Cardama A and Cortes JE. The next generation of therapies for chronic myeloid leukemia. Clinical Lymphoma and Myeloma 2009;9(Suppl 4):S395-403.
  129. Quintas-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT and Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009;115(13):2912-21.
  130. Quintas-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G and Cortes J. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115(17):3935-43.
  131. Quintas-Cardama A, Han X, Kantarjian H and Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114(2):261-3.
  132. Quintas-Cardama A, Kantarjian HM and Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16(2):122-31.
  133. Quintas-Cardama A, Kantarjian H and Cortes J. Homoharringtonine, omacetaxine mepesuccinate and chronic myeloid leukemia circa 2009. Cancer 2009;115(23):5382-93.
  134. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S and Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113(25):6315-21.
  135. Quintas-Cardama A, Kantarjian H, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C and Verstovsek S. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic and Molecular Responses in Patients With Myelofibrosis. Journal of Clinical Oncology 2009;27(28):4760-6.
  136. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J and Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology 2009;27(32):5418-24.
  137. Quintas-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S and Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115(11):2482-90.
  138. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J and Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009;115(24):5746-51.
  139. Pavlovsky C, Kantarjian H and Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present and future. American Journal of Hematology 2009;84(5):287.
  140. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H and Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 2009;23(12):2275-80.
  141. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J and Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2009;115(6):1131-6.
  142. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J and Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. International Journal of Hematology 2009;90(4):522-5.
  143. Silver RT, Cortes J, Waltzman R, Mone M and Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 2009;94(5):743-4.
  144. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H and Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 2009;113(18):4171-8.
  145. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA and Verstovsek S. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal of Clinical Oncology 2009;27(33):5587-93.
  146. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H and Ravandi F._ Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience_. International Journal of Hematology 2009;89(4):489-96.
  147. Verma D, Fava C, Kantarjian H and Cortes J. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. American Journal of Hematology 2009;84(4):256-7.
  148. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB and Cortes J. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes and prognostic significance. Blood 2009;114(11):2232-5.
  149. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H and Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone regimens. Cancer 2009;115(1):101-6.
  150. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintas-Cardama A, Ravandi F, Ault P, Bueso-Ramos C and Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clinical Cancer Research 2009;15(1):368-73.
  151. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H and Keating M. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. Journal of Clinical Oncology 2009;27(10):1637-43.
  152. Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes JE, Medeiros LJ and Lu G. del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genetics and Cytogenetics 2009;192(1):18-23.
  153. Chennupati SK, Govindarhj S, Setzen G and Chiu AG. Adult Burkitt’s lymphoma originating in the sphenoid sinus: Case report and review of the literature. Ear, Nose, and Throat Journal 2009;88(7):E07.
  154. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G and Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2008;113(6):1338-43.
  155. Atallah E, Durand JB, Kantarjian HM and Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110(4):1233-7.
  156. Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J and Keating MJ. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clinical Infectious Diseases 2008;46(7):e69-71.
  157. Bello C and Pinilla-Ibarz J. Modern approaches to treating chronic meylogenous leukemia. Current Oncology Reports 2008;10(5):365-71.
  158. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J and Hazlehurst LA. Stat3 contributes to resistance towards BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics 2008;7(10):3169-75.
  159. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B and Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 2008;113(2):360-6.
  160. Burton T, Larholt K, Pashos C, Peake C, Bookhart B, Corral M, Piech C and McKenzie R. Hematologic outcomes and costs of FDA-approved fixed dosing regimens for erythropoiesis-stimulating agents (ESAs) in chemotherapy-treated cancer patients: real world data from an observational study. Hematology Oncology Pharmacy Association (HOPA), 2008.
  161. Cortes JE._ Imatinib therapy for chronic myeloid leukemia: where do we go now?_ Journal of Clinical Oncology 2008;26(20):3308-9.
  162. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brummendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM and Talpaz M. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22(12):2176-83.
  163. Fava C and Cortes J. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. American Journal of Hematology 2008;83(9):755.
  164. Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S and List A. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008;22(9):1707-11.
  165. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE and Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112(4):981-9.
  166. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X and Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22(3):538-43.
  167. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR and Kantarjian HM. Phase 1 Study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA] in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6.
  168. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O and Cortes J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Seminars in Oncology 2008;35(1 Suppl 1):S1-17.
  169. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M and Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111(3):1039-43.
  170. Hurtado RM, Vargas PV and Cortes JF. Chronic Myeloid Leukemia Current Concepts In Physiopathology and Treatment. Cancerologia 2007;2(2):137-47.
  171. Jabbour E, Cortes JE, Ghanem H, O'Brien S and Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008;8(1):99-110.
  172. Jabbour E, Cortes JE and Kantarjian H. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clinical Lymphoma and Myeloma 2008;8(Suppl 3):S75-81.
  173. Jabbour E, El Ahdab S, Cortes J and Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opinion in Investigational Drugs 2008;17(7):1127-36, 7/2008.
  174. Jabbour E, Cortes JE and Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 2008;112(10):2112-8.
  175. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G and Cortes J. Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008 112(1):53-5.
  176. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J and Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008;112(13):4839-42.
  177. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB and Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 2008;113(10):2154-60.
  178. Jain N, Cortes J, Quintas-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H and Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leukemia Reseach 2008;33(6):837-9.
  179. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ and Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leukemia Research 2008;32(4):643-9.
  180. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F and Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leukemia Research 2008;32(6):936-43.
  181. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H and Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 2008;112(13):5190-2.
  182. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W and Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008;113(5):985-94.
  183. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M and Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 2008;113(7 Suppl):1933-52.
  184. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ and Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113(6):1351-61.
  185. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M and Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008;112(4):837-45.
  186. Kantarjian H, Schiffer C, Jones D and Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111(4):1774-80.
  187. Kharfan-Dabaja MA, Chavez JC and Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 2008;113(5):897-906.
  188. Krijanovski Y, Donato N, Sun H, Meng F, Quintas-Cardama A, Cortes JE and Talpaz M. Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel brc-abl Kinase Domain Mutation. Clinical Leukemia 2008;2(4):267-271.
  189. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M and Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clinical Cancer Research 2008;14(2):509-14.
  190. Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H and Albitar M. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Molecular Cancer Therapeutics 2008;7(12):2246-55.
  191. Manshouri T, Quintas-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM and Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Science 2008;99(6):1265-73.
  192. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E and Scheinberg DA. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008;8:1613-6.
  193. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M and Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leukemia and Lymphoma 2008;49(12):2246-55.
  194. Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J and Daley GQ. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene 2008;27(6):775-82.
  195. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G and Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113(11):3186-91.
  196. Pidala J, Cualing H and Pinilla-Ibarz J. Acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q34, q13). Cancer Genetics and Cytogenetics 2008;182(1):46-9.
  197. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, Shiotsu Y, Shudo A, Akinaga S, Small D, Karp JE and Levis M. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2008;113(17):3938-46.
  198. Quintas-Cardama A and Cortes J._ Homoharringtonine for the treatment of chronic myelogenous leukemia_. Expert Opinion in Pharmacotherapy 2008;9(6):1029-37.
  199. Quintas-Cardama A and Cortes J. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park) 2008;22(4):430-6.
  200. Quintas-Cardama A and Cortes J._ Molecular biology of BCR-ABL1-positive chronic myeloid leukemia_. Blood 2008;113(8):1619-30.
  201. Quintas-Cardama A and Cortes J. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncology 2008;4(5):611-21.
  202. Quintas-Cardama A and Cortes J. Omacetaxine mepesuccinate- a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelcytic leukemia and other myeloid malignancies. IDrugs 2008;11(5):356-72.
  203. Quintas-Cardama A and Cortes J. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL 1 mutant clones. Leukemia Research 2008;32(8):1313-6.
  204. Quintas-Cardama A and Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clinical Cancer Research 2008;14(14):4392-9.
  205. Quintas-Cardama A and Cortes J. Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opinion in Investigational Drugs 2008;17(7):1039-50.
  206. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J and Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide and gemtuzumab ozogamicin. Journal of Clinical Oncology 2008;27(4):504-10.
  207. Quintas-Cardama A, Cortes JE and Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clinical Lymphoma and Myeloma 2008;8(Suppl 3):S82-8.
  208. Quintas-Cardama A, Gibbons DL, Cortes J, Bobadilla D, Slovak ML, Kantarjian H and Abruzzo LV. Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia. Leukemia 2008;22(4):877-8.
  209. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H and Garcia-Manero G. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008; 22(6):1117-24.
  210. Quintas-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G and Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia / polycythemia vera myelofibrosis. Leukemia 2008;22(5):965-70.
  211. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ and Giles FJ. A Phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Investigational New Drugs 2008;26(4):331-8.
  212. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J and Cortes J._ Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia_. Blood 2008;112(3):516-8.
  213. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S and Keating MJ. Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975-80.
  214. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM and Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008;112(5):1628-37.
  215. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ and Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2008;113(25):6330-7.
  216. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ and Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clinical Cancer Research 2008;14(3):721-30.
  217. Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H and Ravandi F. Secondary myelodysplastic sydrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leukemia Research 2008;32(9):1468-71.
  218. Verma D, Kantarjian H, Jain N and Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leukemia and Lymphoma 2008;49(7):1399-402.
  219. Verstovsek S, Manshouri T, Quintas-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W and Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clinical Cancer Research 2008;14(3):788-96.
  220. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D and Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clinical Cancer Research 2008;14(12):3906-15.
  221. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H and Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leukemia Research 2008;33(2):212-7.
  222. Yin C, Jones D, Cortes JE, Kantarjian H, Merzianu M, Medeiros JL and Bueso-Ramos CE. Type B core binding factor B/Smooth muscle myosin heavy chain fusion transcript in myeloid blast phase of chronic myeloid leukemia: correlation with nuclear and cytoplasmic localization of the fusion protein. Clinical Leukemia 2008;2(4):257-60.
  223. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J and Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22(4):808-18.
  224. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintas-Cardama A, Small D, Cortes J and Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Journal of the National Cancer Institute 2008;100(3):184-98.
  225. Alvarez RH, Kantarjian H and Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Seminars in Hematology 2007;44(1 Suppl 1):4-14.
  226. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J and Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007;109(4):713-7.
  227. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H and Ravandi F. Biphenotypic acute leukemia: a case series. British Journal of Haematology 2007;138(2):213-6.
  228. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G and Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007;109(7):1355-9.
  229. Atallah E and Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Current Opinion in Hematology 2007;14(2):138-44.
  230. Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ and Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007;110(10):3547-51.
  231. Atallah E, Kantarjian H and Cortes J. Emerging safety issues with imatinib and other ABL tyrosine kinase inhibitors. Clinical Lymphoma and Myeloma 2007;S3:S105-12.
  232. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F and Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leukemia and Lymphoma 2007;48(6):1150-60.
  233. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S and Keating MJ. Immune anemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. British Journal of Haematology 2007;136(6):800-5.
  234. Cortes J and Deininger M. Chronic Myeloid Leukemia. Informa Healthcare USA, Inc.; 2007
  235. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P and Kantarjian H. Phase I study of lonafarnib (SCH66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007;110(6):1295-302.
  236. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG and Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110(12):4005-11.
  237. Cortes J, Quintas-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D and Kantarjian H._ Phase I study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure_. Cancer 2007;110(9):2000-6.
  238. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A and Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109(8):3207-13.
  239. Darkow T, Henk H, Thomas S, Feng W, Baladi JF, Goldberg G, Hatfield A and Cortes J. Treatment interruptions and non-adherence with Imatinib and associated healthcare costs - a retrospective analysis among managed care patients with chronic myelogenous leukemia. Pharmacoeconomics 2007;25(6):481-96.
  240. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ and Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110(7):1509-19.
  241. Friedman J, Curtis L, Hammill B, Dhillon J, Weaver C, Biswas S, Abernathy A and Schulman K. The Medicare Modernization Act and changes in reimbursement for outpatient chemotherapy: Do patients perceive changes in access to care? Cancer 2007; 110(10):2304-12.
  242. Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W and Prchal JT. Imatinib effect on growth and signal transduction in polycythemia vera. Experimental Hematology 2007;35(6):931-8.
  243. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H and Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109(2):500-2.
  244. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ and Roboz GJ. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia Research 2007;31(7):891-7.
  245. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J and Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia. British Journal of Haematology 2007;136(4):624-7.
  246. Gupta S, Pinilla-Ibarz J and Scheinberg D. Treatment of relapsed and refractory CML and new frontiers in CML therapy. In: Kalaycio, Sekeres and Bolwell, eds. Clinical Malignant Hematology. McGraw-Hill;2
  247. Heidel F, Cortes J, Rucker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Dohner H, Kantarjian H and Fischer T. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer 2007;109(5):907-14.
  248. Jabbour E, Cortes J and Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opinion on Investigational Drugs 2007;16(5):679-87.
  249. Jabbour E, Cortes J, Giles F and Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer Journal 2007;13(6):357-65.
  250. Jabbour E, Cortes JE, Giles FJ, O'Brien S and Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007;109(11):2171-81.
  251. Jabbour E, Cortes J, Giles FJ, O'Brien S and Kantarjian HM. Current and emerging treatment options in chronic myelogenous leukemia. Cancer 2007;109(11):2171-81.
  252. Jabbour E, Cortes J, Giles F, O'Brien S and Kantarjian H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 2007;10(7):468-79.
  253. Jabbour E, Cortes J and Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs. Oncology 2007;21(6):653-62.
  254. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R and deLima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007;110(2):340-44.
  255. Jabbour E, Cortes J, O'Brien S, Giles F and Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Seminars in Hematology 2007;44(1):25-31.
  256. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F and Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clinical Lymphoma and Myeloma 2007;S2:S51-7.
  257. Jabbour E, Kantarjian HM, Abruzzo L, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB and Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110(8):2991-5.
  258. Jabbour E, Kantarjian H and Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opinion in Investigational Drugs 2007;16(3):381-92.
  259. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F and Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007;110(9):2012-8.
  260. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y and Kantarjian H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2007;111(4):1834-9.
  261. Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O'Brien S, Giles F and Albitar M. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 2007;92(2):170-5.
  262. May R, Pinilla-Ibarz J, Dao T, Korontsvit T and Scheinberg D. Peptide epitopes from the WT1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clinical Cancer Research 2007;13(15 Pt 1):4547-4555.
  263. McCullough L. Factors that facilitate adherence to a 12-week walking intervention among breast cancer survivors. Vanderbilt-Ingram Cancer Center Retreat, Vanderbilt University, Nashville, TN, May 2007.
  264. McCullough L. Factors that facilitate adherence to a 12-week walking intervention among breast cancer survivors. Meharry Medical College, Nashville, TN, March 2007.
  265. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT and Goldman JM. Chronic myeloid leukemia - some topical issues. Leukemia 2007;21(7):1347-52.
  266. Kantarjian H and Cortes J. E08 New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML). Leukemia Research 2007;Suppl 2:S16-9.
  267. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarani M and Lokey L. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 2007;109(7):1365-1375.
  268. Kantarjian HM, Giles F, Quintas-Cardama A and Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clinical Cancer Research 2007;13(4):1089-97.
  269. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE and Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109(6):1133-7.
  270. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J and Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109(2):265-73.
  271. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F and Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109(8):1556-60.
  272. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI and Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7.
  273. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad I, Manning JT and Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007;110(6):1303-6.
  274. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E and Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high dose Ara-C: A Phase 1 study. Blood 2007;109(7):2999-3009.
  275. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC and Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Journal of Clinical Investigation 2007;117(9):2408-21.
  276. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G and Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007;109(5):899-906.
  277. Ostronoff F, Bueso-Ramos C, Cortes J and Giralt S. Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution. American Journal of Hematology 2007;82(8):744-7.
  278. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ and Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007;109(1):315-22.
  279. Pan J, Quintas-Cardama A, Manshouri T, Cortes J, Kantarjian H and Verstovsek S. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Science 2007;98(8):1223-5.
  280. Pan J, Quintas-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H and Verstovsek S. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 2007;21(7):1395-404.
  281. Quintas-Cardama A and Cortes J. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. Expert Opinion in Investigational Drugs 2007;16(4):547-57.
  282. Quintas-Cardama A and Cortes J. Nilotinib therapy in chronic myelogenous leukemia. Drugs Today (Barc) 2007;43(10):691-702.
  283. Quintas-Cardama A, Kantarjian H, Abruzzo LV and Cortes J. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia 2007;21(11):2394-6.
  284. Quintas-Cardama A, Kantarjian H and Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6(10):834-48.
  285. Quintas-Cardama A, Kantarjian H and Cortes J. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Leukemia and Lymphoma 2007; 48(4):802-4.
  286. Quintas-Cardama A, Kantarjian H and Cortes J. Tyrosine kinase inhibitors for chronic myelogenous leukemia. New England Journal of Medicine 2007;357(15):1557.
  287. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M and Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109(2):497-9.
  288. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S and Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109(2):248-55.
  289. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W and Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia and Lymphoma 2007;48(2):283-9.
  290. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R and Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. Journal of Clinical Oncology 2007;25(25):3908-14.
  291. Raz T, Nardi V, Azam M, Cortes J and Daley GQ. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood 2007;110(6):2102-9.
  292. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM and Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110(7):2302-2308.
  293. Watters J, Satia J, Kupper L, Swenberg J, Schroeder J and Switzer B. Associations of antioxidant nutrients and oxidative DNA damage in healthy African-American and white adults. Cancer Epidemiology, Biomarkers, and Prevention 2007;16(7):428-1436.
  294. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H and Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109(11):4679-85.
  295. Alvarez RH, Kantarjian HM and Cortes J. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 2006;107(8):1918-29.
  296. Arana-Yi C, Quintas-Cardama A, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H and Verstovsek S. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006;11(8):929-43.
  297. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M and Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. Journal of Clinical Oncology 2006;24(7):1204-8.
  298. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R and Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia. Blood 2006; 108(6):1809-20.
  299. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M and Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006;106(2):346-52.
  300. Connelly-Frost A, Poole C, Satia J, Kupper L, Millikan R and Sandler R. Selenium, apoptosis, and colorectal adenomas. Cancer Epidemiology, Biomarkers, and Prevention 2006;15(3):486-93.
  301. Cortes J. Overcoming drug resistance in chronic myeloid leukemia. Current Opinion in Hematology 2006;13(2):79-86.
  302. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J and Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006;106(6):1306-15.
  303. Coughlin S, Costanza M, Fernandez M, Glanz K, Lee J, Smith S, Stroud L, Tessaro I, Westfall JM, Weissfeld JL and Blumenthal DS. CDC-funded intervention research aimed at promoting colorectal cancer screening in communities. Cancer 2006;17(S5):1196-1204.
  304. DiSantostefano R, Biddle A and Lavelle J. The long-term cost-effectiveness of treatments for benign prostatic hyperplasia. PharmacoEconomics 2006;24(2):171-91.
  305. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M and Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51.
  306. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E and Issa JP. Phase I/II study of the combination of 5-aza-2' -deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108(10):3271-9.
  307. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M and Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research 2006;12(15):4628-35.
  308. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS and Scheinberg DA. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leukemia Research 2006;30(10):1293-8.
  309. Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W and Goldman JM. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37.
  310. Jabbour E, Cortes J and Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Current Opinion in Oncology 2006;18(6):578-83.
  311. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R and de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006;108(4):1421-3.
  312. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S and Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20(10):1767-73.
  313. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G and Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006;107:480-2.
  314. Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M and Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006;106(5):1099-109.
  315. Kantarjian HM and Cortes J. New strategies in chronic myeloid leukemia. International Journal of Hematology 2006;83(4):289-93.
  316. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L and Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine 2006;354(24):2542-51.
  317. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J and Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106(5):1090-8.
  318. Kantarjian HM, Talpaz M, Giles F, O'Brien S and Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Annals of Internal Medicine 2006;145(12):913-23.
  319. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J and Cortes J. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108(6):1835-40.
  320. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV and Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006;108(8):2811-3.
  321. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad, II, Bekele BN, Leitz GJ, Lopez-Roman I, and Estey EH. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrobial Agents and Chemotherapy 2006;50(1):143-7.
  322. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E and Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 2006;107:880-4.
  323. Pinilla-Ibarz J, May R, Korontsvit T and Scheinberg D. Human T cell responses against synthetic HLA 0201 heteroclitic peptides derived from the WT1 oncoprotein. Leukemia 2006;20(11):2025-33.
  324. Quintas-Cardama A, Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H and Verstovsek S. A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia 2006;20(9):1638-40.
  325. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H and Verstovsek S._ Novel approaches in the treatment of systemic mastocytosis_. Cancer 2006;107(7):1429-39.
  326. Quintas-Cardama A and Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clinic Proceedings 2006;81(7):973-88.
  327. Quintas-Cardama A and Cortes J. Kinase inhibitors in chronic myelogenous leukemia. Clinical Advances in Hematology and Oncology 2006;4(5):365-74.
  328. Quintas-Cardama A, Kantarjian H and Cortes J. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncology 2006;2(6):655-65.
  329. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S and Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 2006;107(7):1525-9.
  330. Roboz GJ, Giles FF, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D and Feldman EJ. Phase 1 Study of PTK787/ZK 222584, a small molecule tyrosone kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006;20(6):952-7.
  331. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V and Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006;107:2517-24.
  332. Satia J, McRitchie S, Kupper L and Halbert C. Genetic testing for colon cancer among African-Americans in North Carolina. Preventive Medicine 2006;42:51-59.
  333. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP and Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine 2006;354(24):2531-41.
  334. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG and Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108(5):1497-503.
  335. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, and Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108(4):1158-64.
  336. Tessaro I, Mangone C, Parkar I and Pawar V. Knowledge, barriers and predictors of colorectal cancer screening in an Appalachian church population. Preventing Chronic Disease October 2006. Available from: http://www.cdc.gov/pcd/issues/2006/oct/06_0htm.
  337. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F and Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106(7):1569-80.
  338. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J and Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006;106(9):1974-84.
  339. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F and Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 2006;106(1):120-7.
  340. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML and Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006;106(12):2645-51.
  341. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H and Keating M. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006;106(2):337-45.
  342. Williams E and Papatheofanis F. Calypso 4D localization system with Beacon transponders for continuous tumor localization and tracking during radiation therapy for clinically localized prostate cancer: an early health technology assessment. International Society for Pharmacoeconomics and Outcomes Research. Philadelphia, PA, May 2006.
  343. Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ and Kantarjian H. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leukemia Research 2006;30(11):1365-70.
  344. Verstovsek S, Giles FJ, Quintas-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A and Kantarjian H. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leukemia Research 2006;30(12):1499-505.
  345. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'Brien S M, Jeha S, Andreeff M, Cahill A, Sznol M and Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leukemia Research 2006;30(7):813-22.
  346. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H and Jones D._ t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy_. Cancer 2006;106(8):1730-8.
  347. Bauer-Wu S, Farran CJ. Meaning in life and psycho-spiritual functioning: a comparison of breast cancer survivors and healthy women. Journal of Holistic Nursing: Official Journal of the American Holistic Nurses' Association 2005;23(2):172-90.
  348. Butt Z, Webster K, Eisenstein AR, Beaumont J, Eton D, Masters GA and Cella D. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale. Hematology/Oncology Clinics of North America 2005;19(2):389-420, viii.
  349. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA and Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. Journal of Clinical Oncology 2005;23(12):2805-12.
  350. Cortes J and Kantarjian H. New targeted approaches in chronic myeloid leukemia. Journal of Clinical Oncology 2005;23(26):6316-24.
  351. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB and Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clinical Cancer Research 2005;11(9):3425-32.
  352. DiSantostefano R, Biddle A and Lavelle J. Cost-Effectiveness Analysis of Benign Prostatic Hyperplasia Treatments. (Poster Presentation). International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, Alexandria, VA, May 2005. Received Honorable Mention for Best Poster Presentation.
  353. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G and Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 2005;105(3):1366-7.
  354. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W and Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105(3):940-7.
  355. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM and Reuben JM. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 2005;19(11):1905-11.
  356. Giles FJ, Cortes JE and Kantarjian HM. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Current Molecular Medicine 2005;5(7):615-23.
  357. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM and Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Research 2005;29(6):649-52.
  358. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M and Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 2005;104(3):547-54.
  359. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M and Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clinical Cancer Research 2005;11:7817-24.
  360. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H and Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clinical Cancer Research 2005;11(13):4941-7.
  361. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G and Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. Journal of Clinical Oncology 2005;23(17):3948-56.
  362. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H and Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005;104(3):541-6.
  363. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J and Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005;104(4):777-80.
  364. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J and Cortes J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leukemia and Lymphoma 2005; 46(7):993-7.
  365. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M and Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 2005;103(10):2099-108.
  366. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A and Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4079-88.
  367. Martineau D, Vranken J, Adbi S. Plexus Block: Review of the literature. Journal of Cancer Pain and Symptom Palliation 2005;124(5):807-14.
  368. Merzianu M, Medeiros LJ, Cortes J, Yin C, Lin P, Jones D, Glassman A, Kantarjian H and Huh Y. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. American Journal of Clinical Pathology 2005;1(1):85-93.
  369. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105(6):2281-6.
  370. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H and Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clinical Lymphoma and Myeloma 2005;6(3):234-9.
  371. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H and Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 2005;103(12):2551-7.
  372. Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L and Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clinical Cancer Research 2005;11(17):6247-55.
  373. Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M and Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clinic Proceedings 2005; 80(3):390-402.
  374. Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J and Kurzrock R. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Annals of Oncology 2005;16(1):139-45.
  375. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F and Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005;104(6):1230-6.
  376. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H and Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4070-8.
  377. Wisnivesky JP, McGinn T, Henschke C, Hebert P, Iannuzzi MC and Halm EA. Ethnic disparities in the treatment of stage i non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine 2005;171(10):1158-63.
  378. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM and Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research 2005;11(18):6615-24.
  379. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM and Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004;101(5):999-1008.
  380. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB and Cortes J. Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leukemia Research 2004;28(4):613-8.
  381. Blyler D. Predictors of recurrence for women with breast cancer. American Public Health Association, Washington, D.C., November 2004.
  382. Borthakur G and Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. International Journal of Hematology 2004;79:411-9, 2004.
  383. Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ and Kantarjian H. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101(2):332-6.
  384. Campbell K, James A, Hudson A, Jackson E, Carr C, Farrell D, Tessaro I and Demissie S. Improving multiple behaviors for colorectal cancer prevention Among African-American church members. Health Psychology 2004;23:492-502.
  385. Cortes J and Kantarjian H. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer 2004;100(10):2064-78.
  386. Cortes J, O'Brien S and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104(7):2204-5.
  387. Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, Talpaz M and Kantarjian H. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100:2396-402.
  388. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB and Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Hematology 2004;125(2):187-95.
  389. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E and Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leukemia Research 2004;28(4):353-7.
  390. Giles FJ, Kantarjian H and Cortes J. Novel therapies for patients with chronic myeloid leukemia. Expert Reviews in Anticancer Therapy 2004;4(2):271-82.
  391. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M and Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 2004;100(7):1449-58.
  392. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M and Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clinical Cancer Research 2004;10:2908-17.
  393. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J and Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clinical Cancer Research 2004;10:3371-6.
  394. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R and Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104(3):865-72.
  395. Hennessy B, Giles F, Cortes J, O'Brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H and Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. American Journal of Hematology 2004;77(3):209-14.
  396. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J and Kantarjian HM._ Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies_. Blood 2004;103(5):1635-40.
  397. Jabbour E, Kantarjian H and Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leukemia and Lymphoma 2004;45(11):2187-95.
  398. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D and Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004;104(7):1979-88.
  399. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M and Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clinical Cancer Research 2004;10(1):68-75.
  400. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A and Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103(8):2873-8.
  401. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M and Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101(12):2788-801.
  402. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P and Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. Journal of Clinical Oncology 2004;22(7):1287-92.
  403. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I and Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;100(3):568-73.
  404. Moldenhauer A, Pinilla-Ibarz J, Scheinberg DA, Moore MAS, Frank R and Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with an AML-1 dependent translocation. Journal of Leukocyte Biology 2004;76(3):623-633.
  405. Orsolic N, Giles FJ, Gourdeau H, Golemovic M, Beran M, Cortes J, Freireich EJ, Kantarjian H and Verstovsek S. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. British Journal of Hematology 2004;124(6):727-38.
  406. Pinilla-Ibarz J, Cathcart K and Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037-1042.
  407. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M and Cortes J. Granulocyte-colony-stimulating factor (filgrastin) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004;100(12):2592-7.
  408. Ravandi F, Kantarjian H, Giles F and Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004;100(3):441-54.
  409. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F and Cortes JE. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100(1):116-21.
  410. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M and Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396-407.
  411. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ and Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004;104(6):1624-30.
  412. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M and Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leukemia Research 2004;28(4):373-8.
  413. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H and Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leukemia Research 2004;28(6):657-60.
  414. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H and Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemotherapy and Pharmacology 2003;51(1):81-6.
  415. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E and Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 2003;51(1):87-90.
  416. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ and Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003;102:1866-8.
  417. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H and Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Research 2003; 27(10):887-91.
  418. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H and Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia Research 2003;27:301-4.
  419. Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F, Estey E and Kantarjian HM. Phase I study of oral topotecan in hematological malignancies. Clinical Cancer Research 2003;9:4084-91.
  420. Blyler D and Weihs K. Surviving breast cancer: The influence of recent negative life events. American Psychosomatic Society, Phoenix, AZ, March 2003.
  421. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R and Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine 2003;348(13):1201-14.
  422. Cortes J and Albitar M. Acute lymphoblastic leukemia. In: Atlas of Cancer. Pennsylvania: Lippincott Williams & Wilkins; 2003:287-
  423. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M and Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101(5):1692-7.
  424. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES and Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101(12):4714-6.
  425. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A and Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003;97(11):2760-6.
  426. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M and Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003;102(1):83-6.
  427. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M and Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2003;97(5):1234-41.
  428. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S and Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101(10):3794-800.
  429. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W and Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98(6):1105-13.
  430. Estey E, Giles F, Cortes J, Beran M, Koller C, O'Brien S, Pierce S and Kantarjian H. Treatment of AML & high-risk MDS at M.D. Anderson: The lone star approach. In: Acute Leukemias IX. New York: Springer-Verlag Berlin Heidelberg: 2003; 394-
  431. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S and Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leukemia Research 2003;27(6):475-9.
  432. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J and Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood 2003;102(9):3097-9.
  433. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N and Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101(9):3413-5.
  434. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP and Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98(4):773-8.
  435. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M and Kantarjian HM._ Chronic myelogenous leukemia: a review and update of therapeutic strategies_. Cancer 2003;98(3):437-57.
  436. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W and Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 2003;97(12):3010-6.
  437. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE and Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003;88(8):853-63.
  438. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P and Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. British Journal of Haematology 2003;121:578-85.
  439. Giles FJ, Cortes JE, Halliburton TA, Mallard SJ, Estey EH, Waddelow TA and Lim JT. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Annals of Pharmacotherapy 2003;37(9):1182-5.
  440. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH and Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.
  441. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM and Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research 2003;27:1091-6.
  442. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF and Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research 2003;27:1077-83.
  443. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA and Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. Journal of Clinical Oncology 2003;21(9):1722-7.
  444. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM and Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
  445. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ and O'Brien SM. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemotherapy and Pharmacology 2003;52:223-8.
  446. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W and Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of Clinical Oncology 2003;21(6):1167-73.
  447. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ and Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003:97(4):1033-41.
  448. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R and Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101(1):97-100.
  449. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W and Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102(7):2379-86.
  450. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M and Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003;98(3):522-8.
  451. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M and Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003;98(12):2636-42.
  452. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E and Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 2003;98(1):81-5.
  453. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB and Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 2003;98(7):1430-7.
  454. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J and Arlinghaus R. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clinical Cancer Research 2003;9(1):160-6.
  455. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB and Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-5.
  456. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S and Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;97(9):2225-8.
  457. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM and Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica 2003;88(7):733-6.
  458. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M and Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003;102(13):4527-34.
  459. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S and Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003;97(9):2218-24.
  460. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A and Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clinical Cancer Research 2003;9:976-80.
  461. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M and Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97:450-6.
  462. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K and Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98(9):1905-11.
  463. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E and Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98(5):888-93.
  464. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M and Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98(12):2657-63.
  465. Schwartz J, Pinilla-Ibarz J and Scheinberg D. Novel targeted and immunotherapeutic strategies in chronic myelogenous leukemia. Seminars of Hematology 2003;40:87-96.
  466. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, O'Brien S, Albitar M and Kantarjian H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology 2003;123(3):436-41, 2003.
  467. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J and Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102(12):3906-11.
  468. Tsao AS, Kantarjian H, Cortes J, O'Brien S and Talpaz M._ Imatinib mesylate causes hypopigmentation in the skin_. Cancer 2003;98(11):2483-7.
  469. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E and Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research 2003;27(10):893-7.
  470. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM and Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemotherapy and Pharmacology 2003;52:229-34.
  471. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM and Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology 2003;52(6):449-52.
  472. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H and Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;97(6):1481-7.
  473. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ and Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97(7):1711-20.
  474. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S and Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 2003;17:1100-3.
  475. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M and Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 2003;97:1248-52.
  476. Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S and Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 2003;97(9):2212-7.
  477. Williams E and Papatheofanis F. 90Y Ibritumomab tiuxetan [Zevalin™] for treatment of refractory or relapsing low-grade or follicular non-Hodgkin's lymphoma (NHL): a cost utility-study. Society of Medical Decision Making, Chicago, IL, October 2003.
  478. de Torres JP, Kenney L and Celli B. Primary T-cell lymphoma: Report of a case and review of the literature. Archivos de Bronconeumologia 2002;38(12):596-8.
  479. Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C and Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 2002;7(3):179-85.
  480. Ault P, Cortes J, Koller C, Kaled ES and Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Research 2002;26:881-4.
  481. Cortes JE, Kurzrock R and Kantarjian HM. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Seminars in Hematology 2002;39(3):26-30.
  482. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S and Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492-9.
  483. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E and Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology 2002;50(60):497-500.
  484. Dabaja BS, Ha CS, Thomas DA, Wilder RB, Gopal R, Cortes J, Bueso-Ramos C, Hess MA, Cox JD and Kantarjian HM. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 2002;94:2738-44.
  485. Druker BJ, O'Brien SG, Cortes J and Radich J. Chronic myelogenous leukemia. Hematology / the Education Program of the American Society of Hematology 2002:111-35.
  486. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE and Kantarjian HM. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99(11):4222-4.
  487. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA and Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99(12):4343-9.
  488. Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM and Estey E. A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica 2002;87:804-7.
  489. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL and Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clinical Cancer Research 2002;8:2134-41.
  490. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J and Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. Journal of Clinical Oncology 2002;20:656-64.
  491. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H and Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica 2002;87(10):1114-6.
  492. Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, Manshouri T, Rogers A, Keating MJ, Talpaz M, O'Brien S and Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. British Journal of Haematology 2002;119:38-45.
  493. Hui YF, Giles FJ and Cortes JE. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome-recall following different chemotherapy agents. Investigational New Drugs 2002;20:49-53.
  494. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E and Albitar M. Differences in CD33 intensity between various myeloid neoplasms. American Journal of Clinical Pathology 2002;118(4):560-6.
  495. Kantarjian HM, Cortes JE, Rowe JM and Kurzrock R. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Seminars in Hematology 2002;39(3):36-8.
  496. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D and Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
  497. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R and Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100(5):1590-5.
  498. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R and Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research 2002;8:2167-76.
  499. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ and Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research 2002;8:2177-87.
  500. Kurzrock R, Cortes J and Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Seminars in Hematology 2002;39(4):20-4.
  501. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M and Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002;94:2024-32.
  502. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Fiere D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T and Estey E. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002;16(9):1615-21.
  503. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S and Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leukemia Research 2002;26:643-9.
  504. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S and Kantarjian H. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 2002;94(3):773-9.
  505. Thomas DA, Cortes J and Kantarjian HM._ New agents in the treatment of acute lymphocytic leukaemia_. Best Practice & Research. Clinical Haematology 2002;15(4):771-90.
  506. Thomas DA and Cortes J, Bueso-Ramos C, Kantarjian H and Hagemeister FB. High-grade non-Hodgkin's lymphomas. In: Atlas of Clinical Oncology: Malignant Lymphomas. New York: BC Decker, Inc. Publications; 2002:152-
  507. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ and Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leukemia and Lymphoma 2002;43:767-72.
  508. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H and Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. British Journal of Haematology 2002;118:151-6.
  509. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A and Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002;99:2265-7.
  510. Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J and Albitar M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer 2002;94:1517-21.
  511. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC and Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 2002;94:2416-25.
  512. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S and Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001;92:1999-2015.
  513. Cathcart K, Pinilla-Ibarz J and Scheinberg DA. Immunotherapeutics strategies in CML. In: Carella et al., ed. Chronic Myeloid Leukemia: Biology and Treatment. London: Martin Dunitz Publishers; 2001:507-
  514. Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. In: Hematology/Oncology Clinics of North America. Pennsylvania: W. B. Saunders Company; 2001:145-
  515. Cortes JE, Aguayo A and Kantarjian H. Chronic leukemias. In: Cancer Management: A Multidisciplinary Approach, 5. New York: PRR Publications; 2001:663-
  516. Cortes JE, Aguayo A and Kantarjian H. Myelodysplastic syndromes. In: Cancer Management: Multidisciplinary Approach, 5. New York: PRR Publications; 2001:687-7
  517. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M and Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001;92:7-14.
  518. Cortes JE and Kantarjian H. Chronic leukemias. In: Conn's Current Therapy. W. B. Pennsylvania: W. B. Saunders Company; 2001:454-
  519. Cortes J, O'Brien S, Loscertales J, Kantarjian H, Giles F, Thomas D, Koller C and Keating M. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 2001;92:2016-22.
  520. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ and Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leukemia and Lymphoma 2001;42(3):329-37.
  521. Estey E, Koller C, Cortes J, Reed P, Freireich E, Giles F and Kantarjian H. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leukemia and Lymphoma 2001;42:309-16.
  522. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM and Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:3575-83.
  523. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J and Estey E. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia and Lymphoma 2001;40:511-20.
  524. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J and Kantarjian HM. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. Journal of Clinical Oncology 2001;19:762-71.
  525. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A and Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Investigational New Drugs 2001;19(1):13-20.
  526. Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M and Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leukemia and Lymphoma 2001;41:309-19.
  527. Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, Cortes J, Giles FJ and O'Brien S. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer 2001;92:2501-7.
  528. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S and Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. Journal of Clinical Oncology 2001;19:4165-72.
  529. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S and Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology 2001;19:1414-20.
  530. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S and Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology 2001;19(8):2165-70.
  531. Ravandi F, Hayes K, Cortes J, Albitar M, Glassman A, Talpaz M and Kantarjian HM. Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia. Cancer 2001;91(9):1704-8.
  532. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB and Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 2001;91(11):1964-72.
  533. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S and Kantarjian HM. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 2001;98:1708-13.
  534. Thomas DA, Giles FJ, Cortes J, Albitar M and Kantarjian HM. Antiangiogenic therapy in leukemia. Acta Haematology 2001;106(4):190-207.
  535. Aguayo A, Cortes J and Kantarjian H. Myelodysplastic syndromes. In: Cancer Management: A Multidisciplinary Approach, 4. New York: PRR Publications: New York; 2000:681-
  536. Cortes JE, Aguayo A and Kantarjian H. Chronic leukemias. In: Cancer Management: A Multidisciplinary Approach, 4. New York: PRR Publications; 2000:657-
  537. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M and Kantarjian H. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leukemia and Lymphoma 2000:36:479-84.
  538. Cortes J and Kantarjian HM. Promising approaches in acute leukemia. Investigational New Drugs 2000;18:57-82.
  539. Cortes J, O'Brien S and Kantarjian H. A guide to the use of interferon alpha in the management of chronic myelogenous leukemia. BioDrugs 2000;14:211-20.
  540. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z and Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000;89(9):1976-82.
  541. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M and Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma 2000;36(3-4):263-73.
  542. Hui YF and Cortes JE. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 2000;20(10):1221-3.
  543. Jurcic J, Cathcart K, Pinilla-Ibarz J and Scheinberg DA. Immunotherapy of leukemias. Current Opinion in Hematology 2000;7(4):247-54.
  544. Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles FJ, Pierce S and Albitar M. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer 2000;88:570-6.
  545. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S and Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Journal of Clinical Oncology 2000;18:547-61.
  546. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B and O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology 2000;18(20):3513-21.
  547. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M and May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clinical Cancer Research 2000; 6:1401-9.
  548. Pinilla-Ibarz J, Cathcart K and Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Reviews 2000;14:11-120.
  549. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J and Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95:1781-7.
  550. Ravandi-Kashani F, Cortes J and Giles FJ. Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome. Leukemia and Lymphoma 2000;36:631-7.
  551. Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB and Kantarjian H. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical Cancer Research 2000:6(1):147-52.
  552. Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H and Kurzrock R. Autoantibodies to Abl and Bcr proteins. Leukemia 2000;14:1661-6.
  553. Tessaro I and Herman C. Changes in knowledge and perception of clinical skills of public health nurses for breast and cervical cancer control. Cancer Nursing 2000;23:401-5.